個(gè)人簡(jiǎn)介：

Dr. An is the founder of Curegenix. He is an expert in WNT signaling research with more than 20 years of drug discovery experiences in pharmaceutical industry. Prior to founding Curegenix, he was a Principlal Scientist / Project Leader at Amgen and a program director at Tularik in the US. He obtained an MD degree from Peking University Medical School and a PhD degree in Molecular Biology / Biochemistry from the University of Missouri-Columbia. After postdoctoral training in immunology at the University of California, San Francisco (UCSF), Dr. An became an assistant professor in the Department of Medicine at UCSF.

公司簡(jiǎn)介：

應用國際先進(jìn)技術(shù)，研發(fā)全球首創(chuàng )First-in-class抗腫瘤、抗纖維化新藥 。廣州開(kāi)發(fā)區科技領(lǐng)軍人才，廣州市創(chuàng )業(yè)領(lǐng)軍人才，國家十二五重大新藥創(chuàng )制專(zhuān)項，著(zhù)名風(fēng)險投資機構及跨國藥廠(chǎng)支持 。磷酸源生萘啶CGX1321完成中美雙報，開(kāi)展國際多中心臨床試驗，在全球十多家頂級臨床中心完成臨床2a期試驗（Harvard, Johns Hopkins, Duke, 北京腫瘤醫院等) 。臨床試驗結果在美國臨床腫瘤學(xué)會(huì ) (ASCO) 2023年會(huì )上應邀做口頭報告 。自主研發(fā)項目聚焦WNT通路抑制劑，不涉獵其它靶點(diǎn)。將借助研發(fā)平臺和豐富經(jīng)驗，為業(yè)內同仁提供臨床前研究服務(wù)、中美臨床試驗咨詢(xún)。